Your session is about to expire
← Back to Search
Other
TCMCB07 for Cachexia
Phase 1
Waitlist Available
Led By Maria Bermudez, MD, CPI
Research Sponsored by Endevica Bio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Summary
This trial is testing a new drug called TCMCB07 to help cancer patients who are experiencing severe weight loss and weakness due to cachexia. The drug aims to improve their appetite and energy levels, making them feel stronger and healthier.
Eligible Conditions
- Cachexia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with abnormal vital signs
Number of people with abnormal Electrocardiograms
Number of people with abnormal laboratory test results
+2 moreSecondary study objectives
Area under the plasma concentration versus time curve (AUC)
Peak Plasma Concentration (Cmax)
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TCMCB07Experimental Treatment1 Intervention
once daily subcutaneous injection
Group II: PlaceboPlacebo Group1 Intervention
once daily subcutaneous injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TCMCB07
2022
Completed Phase 1
~80
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Endevica BioLead Sponsor
Maria Bermudez, MD, CPIPrincipal InvestigatorQuotient Sciences
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger